Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depigoid Acarus siro is a depigmented, polymerized allergen extract used for subcutaneous immunotherapy (SCIT) targeting allergy to the storage mite *Acarus siro* (flour mite). The product is designed to desensitize individuals with IgE-mediated allergy to *Acarus siro*, which can cause symptoms such as asthma, rhinitis, skin reactions, and in rare cases anaphylaxis. The mechanism of action involves gradual exposure to increasing doses of the allergen extract, leading to immune tolerance and reduction in allergic symptoms. Depigoid extracts are specifically processed by depigmentation and polymerization to reduce allergenicity while maintaining immunogenicity. This therapy is primarily indicated for patients with confirmed sensitization and clinical symptoms due to *Acarus siro* exposure[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Depigoid Acarus siro.